Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

(2020) Shizuya Yamashita et al.   Current Atherosclerosis Reports

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

(2020) Yusuke Sasaki et al.   Scientific Reports

Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

(2020) Alessandro Mantovani et al.   GUT

Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease

(2019) Nobuharu Tamaki et al.   Scientific Reports

Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in NAFLD

(2019) Veeral H. Ajmera et al.   HEPATOLOGY

Magnetic Resonance vs Transient Elastography Analysis of Patients With Non-alcoholic Fatty Liver Disease: a Systematic Review and Pooled Analysis of Individual Participants

(2018) Cynthia Hsu et al.   Clinical Gastroenterology and Hepatology

Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia

(2018) Shizuya Yamashita et al.   Journal of Clinical Lipidology

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

(2018) Amedeo Lonardo et al.   JOURNAL OF HEPATOLOGY

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

(2018) Ikuro Matsuba et al.   Journal of Diabetes Investigation

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

(2018) Saumya Jayakumar et al.   JOURNAL OF HEPATOLOGY

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Current and future pharmacological therapies for NAFLD/NASH

(2017) Yoshio Sumida et al.   JOURNAL OF GASTROENTEROLOGY

Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH)

(2017) R. Loomba et al.   JOURNAL OF HEPATOLOGY

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

(2017) Yasushi Honda et al.   Scientific Reports

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

(2016) Nathalie Hennuyer et al.   ATHEROSCLEROSIS

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography

(2016) Kento Imajo et al.   GASTROENTEROLOGY

MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice

(2016) Parambir S. Dulai et al.   JOURNAL OF HEPATOLOGY

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis

(2016) Janki Patel et al.   Therapeutic Advances in Gastroenterology

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

(2015) Sven Francque et al.   JOURNAL OF HEPATOLOGY

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis

(2015) Chiara Saponaro et al.   Nutrients

Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids

(2013) Laurent Camont et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY